Journal of Multiple Sclerosis and Neuroimmunology

Review Article

December 31, 2024

Eculizumab Therapy in Neuromyelitis Optica Spectrum Disorder

Jee Eun Kim, Suk-Won Ahn

J Mult Scler Neuroimmunol. 2024;15(2):43-48.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that causes recurrent inflammation in the central nervous system which has poor prognosis without appropriate treatment. Complement activation mediated by...

Review Article

December 31, 2024

The Clinical Utility of the Ocrelizumab for the Patients with Multiple Sclerorsis

Suk-Won Ahn

J Mult Scler Neuroimmunol. 2024;15(2):49-54.

Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory disease of the central nervous system, primarily affecting young adults, and is characterized by demyelination and neurodegeneration. Although several disease-modifying therapies (DMTs)...

Review Article

December 31, 2024

Summary of Cladribine (from Development to Clinical and Practical Treatment)

Kyong Jin Shin

J Mult Scler Neuroimmunol. 2024;15(2):55-58.

Multiple sclerosis (MS) is a chronic inflammatory central nervous system disorder involving autoreactive T and B cells, causing demyelination and axonal damage. Cladribine (Mavenclad®, Merck, Rahway, NJ, USA), an oral...

Original Article

December 31, 2024

National Consensus Guidance for Management of Refractory Myasthenia Gravis

Hyung-Soo Lee, Hye Yoon Chung, Seung Woo Kim, et al.

J Mult Scler Neuroimmunol. 2024;15(2):59-71.

Background: Despite advances in treatment, 10-15% of the patients with myasthenia gravis (MG) are refractory to convention therapies, have severe disease, and are more likely to experience frequent clinical exacerbation....

Original Article

December 31, 2024

Temporal Association between Thymoma Recurrence and Exacerbation of Myasthenia Gravis

Byeong Cheol Oh, Ha Young Shin, Young Ho Yang, et al.

J Mult Scler Neuroimmunol. 2024;15(2):72-80.

Background: This study investigates the potential link between myasthenia gravis (MG) exacerbation and thymoma recurrence in patients with thymoma-associated MG (TAMG). Methods: We conducted a retrospective medical record analysis at Severance...

Case Report

December 31, 2024

A Case Report of MOG Antibody-Associated Disease (MOGAD) with Isolated Brainstem and Spinal Cord Involvement

Ye Lin Kim, Juhee Chae, Sun-Young Oh

J Mult Scler Neuroimmunol. 2024;15(2):81-84.

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a central nervous system demyelinating disorder with diverse clinical presentations, including optic neuritis, myelitis, and acute disseminated encephalomyelitis. Specific radiological features, such as...

Neuroimage

December 31, 2024

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as a Diffuse Pachymeningitis

Jun-Soon Kim

J Mult Scler Neuroimmunol. 2024;15(2):85-86.

Current Issue: Volume 15(2); Dec 2024

Journal of Multiple
Sclerosis and
Neuroimmunology

Print ISSN: 2733-8290
Online ISSN: 2951-2972

MOST VIEWED MOST CITED

7,030	Understanding MRI Features of Multiple Sclerosis: Based on the 2017 McDonald Criteria
3,264	Rituximab Treatment for Neuroimmunologic Disorders
3,181	Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study
3,079	National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
2,631	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review

+more

Cited By 3	Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study
Cited By 1	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review
Cited By 1	National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Cited By 1	A Case of Post-Infective Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease

+more

Editorial Office: Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-3153 E-mail: icandr@cau.ac.kr